Scryb Inc. Forum: Community User: Philipp85

*** = H.o.m.o.s

Gab's da nicht mal einen Hemopalm...? ...oder sollte es heißen, dass sich *** die Palme wedeln...? 🙄😎

Dümpelt....und dümpelt....ohne positive News gibt's keinen Anstieg...

Nicht unbedingt negativ, da das in der Regel eh nicht nachhaltig ist.

Nicht mal mehr das gepushe vom Polli bringt noch was!

Hello Davide, Thank you for your email.  The Company recently provided an update on HemoPalm development which can be found here: https://www.relaymedical.com/blog/2019/2/7/relay-medical-reports-progress-on-enhanced-hemopalm-system-design-and-provides-update-on-product-development-and-market-advancement-activities The purpose of Voice of customer studies and other business development activities you mentioned is to identify the complete set of product requirements in relation to potential buyers/partners/strategic relationships for commercialization. This does not only pertain to functionality of the technology but to how the technology is commercialized as a product and how the HemoPalm integrates with the existing product offerings of these potential acquirers. In order to do this effectively the company conducts thorough correspondence with buyers and strategic partners to gain a complete understanding as to how the device fits into the buyers production facilities/capabilities to address current and additional product opportunities and productizes the technology to meet these requirements and remain flexible enough to appeal to multiple markets/buyers.  As outlined in the release, there are several key areas that have been guided and improved on as a result of this development and analysis including the reduction of cartridge cost and sample preparation which are critical areas of interest for multi-national buyers.  Unfortunately this part of productization led to a slow news period in 2018 and I understand that it may not seem as exciting but this is one of, if not the most important part of ensuring that the technology is productized to be bought or licensed by the major acquirers in the industry. In regards to the Auto-Ultrfiltration technology the Company has continued to manage the IP and has conducted preliminary analysis on potential applications and fit but is currently focused on more near term high-value projects like the HemoPalm and Pharmatrac.  In 2018 the company grew from a single-asset research and development company to a organization with the capacity to not only commercialize the HemoPalm technology but to bring multiple high potential technologies to market. I expect that the market will recognize and reflect this value in 2019. Thanks again for reaching out Davide, in the future please feel free to contact me directly via the co-ordinates below.  Regards, Clark W. Clark Kent, President Relay Medical Corp.

Das mit dem Erfolg kann man wohl abhaken. Alles eine einzige Luftnummer ohne das was dahinter steckt! Und von ihrem Zauberprodukt Hemopalm hört man schon erst gar nichts mehr!

Viel Erfolg weiterhin:-)

Bin bei 40 cent rein... Seitdem trauer pur .... Aber ich muss leider bleiben und hoffen .... Bei PUF ventures wars das selbe spiel.. bei 0.90 rein .. absturz.. und jz mit agra voll im plus.. who knows

So bin raus. Trotz Verluste und anderweitig investiert

Was?

Lang & Schwarz...mehr sog i ned ; )

Komplett Absturz. Für mich unverständlich nach mit AgraFlora. Was ist hier los ?

Heute bei 14 Cent. Morgen wieder bei 12 :D

Ich bin nicht nachtragend.. ;-)

Ich bin nicht nachtragend.. ;-)